One aspect of the present disclosure can include a method for reducing or alleviating inflammation in the digestive tract of a subject in need thereof that consumes a disruptive dietary component. One step of the method can include assaying a previously obtained fecal sample from the subject for the presence of one or more Proteobacteria and an activity level of a peroxidase enzyme. The subject can decrease ingestion of the disruptive dietary component if the assayed presence of the one or more Proteobacteria and the activity level of the peroxidase enzyme are increased as compared to control levels.

Novel compositions of recombinant human CC10 protein have been generated by chemically modifying the pure protein in vitro. Several new synthetic preparations containing isoforms of chemically modified rhCC10 have been generated by processes that utilize reactive oxygen species and reactive nitrogen species. These preparations contain novel isoforms of rhCC10 which have been characterized with enhanced or altered biological properties compared to the unmodified protein. Preparations containing novel isoforms may be used as standards to identify and characterize naturally occurring isoforms of native CC10 protein from blood or urine and ultimately to measure new CC10-based biomarkers to assess patient disease status. These preparations may also be used to treat respiratory, autoimmune, inflammatory, and other medical conditions that are not effectively treated with the unmodified protein.

Compositions comprising a combination of myeloperoxidase and a peroxide-producing oxidase and methods of using the compositions to inactivate gram negative bacterial lipopolysaccharides and lipid A endotoxin are provided.

A method of treating at least one of septicemia, endotoxemia or a bacterial infection in a subject can include administering to the subject a composition containing a therapeutically effective amount of a haloperoxidase. The haloperoxidase can be myeloperoxidase or eosinophil peroxidase. The haloperoxidase can inhibit lipopolysaccharide or Lipid A activity in the subject; as a non-limiting example, the haloperoxidase is not engaged in active haloperoxidase activity, but available for LPS or Lipid A binding and inhibition.

A liquid detergent composition, preferably a liquid manual dishwashing detergent composition, comprising one or more hydroperoxy fatty acid producing enzymes selected from the group consisting of: arachidonate lipoxygenases, alpha-dioxygenases, and mixtures thereof, preferably alpha-dioxygenases, a surfactant system and a liquid carrier (i.e., water). Methods of washing comprising the liquid detergent composition are also provided.

Described herein are methods and compositions relating to methods of inhibiting neutrophils, e.g., inhibiting NET release or NETosis, by means of a DEspR inhibitor, e.g., an anti-DEspR antibody reagent. In some embodiments, the methods can relate to the treatment of a disease, e.g., cancer or a disease wherein neutrophils; NETs; or NETosing or NETting neutrophils contribute to pathogenesis, chronicity, or worsening of disease. In some embodiments, the DEspR inhibitor can be a bi-specific reagent or an antibody-drug conjugate.

The present invention relates to methods of modulating the expression and/or activity of Myeloperoxidase (MPO) in a mammalian subject, by modulating ex vivo and/or in vivo MPO levels and/or activity in undifferentiated bone marrow (BM) cells of the subject. The invention further provide therapeutic methods and compositions for treating MPO-related disorders.

The present invention relates to methods of modulating the expression and/or activity of Myeloperoxidase (MPO) in a mammalian subject, by modulating ex vivo and/or in vivo MPO levels and/or activity in undifferentiated bone marrow (BM) cells of the subject. The invention further provides therapeutic methods and compositions for treating MPO-related disorders.

One aspect of the present disclosure can include a method for reducing or alleviating inflammation in the digestive tract of a subject in need thereof that consumes a disruptive dietary component. One step of the method can include assaying a previously obtained fecal sample from the subject for the presence of one or more Proteobacteria and an activity level of a peroxidase enzyme. The subject can decrease ingestion of the disruptive dietary component if the assayed presence of the one or more Proteobacteria and the activity level of the peroxidase enzyme are increased as compared to control levels.

Compositions comprising a combination of myeloperoxidase and a peroxide-producing oxidase and methods of using the compositions to inactivate gram negative bacterial lipopolysaccharides and lipid A endotoxin are provided.